Amplitude Ventures

Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeutic and commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030. It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.

DrugBank is a comprehensive online database that contains information on drugs and drug targets. They organize, collect, and curate all the important information about drugs into a single unified resource. It also combines detailed drug such as pharmacological, pharmaceutical, and chemical data with the comprehensive drug target sequence, structure, and pathway information. DrugBank is widely used by the drug industry, medicinal chemists, pharmacists, physicians, students, and the general public. It was founded in 2015 and is headquartered in Edmonton, AB, USA.

Celsius Therapeutics is a biotechnology company focused on developing innovative medicines to treat complex diseases, including autoimmunity and cancer. Founded in 2017 and based in Cambridge, Massachusetts, the company leverages advanced techniques such as single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. By systematically applying single-cell sequencing and analyzing extensive datasets with sophisticated algorithms, Celsius Therapeutics aims to discover critical biomarkers and precision therapies that enhance patient care and enable clinicians to identify genes that play a causal role in various conditions.

Congruence Therapeutics is a biotechnology company focused on drug discovery for diseases associated with protein misfolding. By integrating computational and experimental approaches, the company develops novel small molecules aimed at treating rare diseases. Utilizing structural bioinformatics, computational chemistry, and machine learning, Congruence has established an in silico platform that facilitates the design and validation of pharmacological stabilizers. This innovative approach allows researchers to create targeted therapeutic options for conditions linked to protein misfolding, advancing the field of biotechnology and improving treatment outcomes for affected patients.

Gandeeva Therapeutics is a biotechnology company focused on drug discovery, utilizing a proprietary platform that integrates cryogenic electron microscopy and machine learning. This platform enables the detailed characterization of protein-drug interactions at the atomic level, facilitating insights into protein function and interactions. The company's approach includes target prediction and validation, hit identification through virtual and fragment library screening, and lead optimization. Gandeeva Therapeutics is developing innovative therapeutics aimed at key protein-protein interactions, particularly in oncology, with a robust preclinical pipeline that addresses challenging cancers using novel protein interaction modulators, such as interfacial glues and allosteric inhibitors. This methodology aims to reduce the risks associated with late-stage clinical failures in drug development.

InVivo AI is a Montreal-based company founded in 2017 that specializes in using artificial intelligence to enhance pharmaceutical research and development. The company primarily focuses on preclinical toxicology, aiming to improve the efficiency and effectiveness of drug development processes. By leveraging advanced AI technologies, InVivo AI seeks to transform traditional methodologies in the pharmaceutical industry, ultimately contributing to faster and more reliable outcomes in drug safety assessments.

Prilenia Therapeutics B.V., a clinical stage biotech company, researches and develops products for movement disorders and neurodegenerative diseases affecting adults and children. It offers Pridopidine, an orally bioavailable small molecule investigational drug for huntington disease, amyotrophic lateral sclerosis, Parkinson’s disease levodopa induced dyskinesia, neurodegenerative eye disease, Parkinson’s disease, rett syndrome, fragile X, and Alzheimer’s disease. The company was founded in 2018 and is based in the Netherlands.

Thryv Therapeutics is a biopharmaceutical company focused on developing therapies for long QT syndrome, a genetic disorder characterized by prolonged ventricular repolarization, which can lead to life-threatening arrhythmias. The company's research centers on SGK-1, a regulator of sodium channels in heart cells, which is implicated in the overactivity associated with long QT syndrome. By targeting this kinase, Thryv aims to address the underlying causes of the disorder and improve treatment options for affected patients. Based in Laval, Canada, the company is committed to advancing its pipeline to enhance patient outcomes in this critical area of cardiovascular health.

Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.

Giiant Pharma is a preclinical-stage biotechnology company focused on developing innovative therapies for inflammatory bowel diseases (IBD). Utilizing its proprietary Precision Delivery technology platform, Giiant designs gut-restricted, tissue-specific small molecule drug therapeutics that target specific biological pathways in gastroenterology. The company's lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug, which aims to improve drug tolerability while enhancing therapeutic effects. By releasing its active form specifically in the colon, Giiant's approach allows for targeted treatment at the site of inflammation, potentially preventing the worsening of patients' conditions.

Notch Therapeutics Inc. is an immune cell therapy company based in Toronto, Canada, focused on developing gene-edited allogenic T cell therapies for cancer treatment. Established in 2018, the company utilizes an induced pluripotent stem cell (iPSC) platform that enables precise control of Notch signaling. This innovative technology addresses key limitations in cell therapy development by allowing for the design and manufacture of a consistent supply of therapeutic T cells. Notch Therapeutics specializes in iPSC AlloCAR therapy products aimed at treating conditions such as non-Hodgkin lymphoma, leukemia, and multiple myeloma, enabling healthcare professionals to engineer stem cells tailored to the specific biological challenges presented by complex diseases.

Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.

Profound Medical Corp. is a medical technology company that specializes in the development of magnetic resonance guided ablation procedures for treating conditions such as prostate disease, uterine fibroids, and palliative pain from bone metastases. The company's lead product, the TULSA-PRO system, combines real-time MRI guidance with robotically driven ultrasound to provide precise, non-invasive tissue ablation. This system is designed to work seamlessly with existing MRI infrastructure in hospitals and treatment facilities. Additionally, Profound Medical offers the Sonalleve platform, which targets uterine fibroids and bone metastases. The company is headquartered in Mississauga, Canada, and has established a co-development agreement with GE Healthcare to enhance access to its TULSA-PRO system. Profound Medical is committed to improving patient care by providing safe and effective treatment options that allow for quicker recovery and a return to daily activities.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on the development and commercialization of etripamil, a novel calcium channel blocker targeting various cardiovascular conditions. Etripamil is designed as a rapid-onset nasal spray for the self-administration by patients, specifically to terminate episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently advancing etripamil through Phase III clinical trials for PSVT in the United States and Canada, as well as conducting Phase II trials for patients with atrial fibrillation experiencing a rapid ventricular rate. Founded in 2003, Milestone aims to address unmet medical needs in the treatment of transient cardiovascular conditions, including atrial fibrillation and angina.

Clementia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Montreal, Canada, focused on developing innovative treatments for patients with ultra-rare bone disorders and other diseases characterized by high unmet medical needs. Founded in 2010, the company specializes in disease-modifying therapies, with its lead product candidate being palovarotene, an oral small molecule. Palovarotene has demonstrated significant potential in preventing abnormal bone formation and fibrosis across various tissues. The candidate is currently undergoing evaluation in the Phase III MOVE trial, targeting conditions such as fibrodysplasia ossificans progressive and multiple osteochondromas, as well as dry eye disease. Clementia's commitment to addressing debilitating health issues highlights its role in advancing treatment options for affected patients.

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, that specializes in the discovery, development, and commercialization of biotherapeutics, primarily for cancer treatment. The company’s leading candidates include ZW25, a bispecific antibody currently undergoing Phase I and II clinical trials targeting various cancers, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs advanced computational biotechnology techniques, utilizing proprietary molecular modeling and high-performance computing to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships and collaborations with several major pharmaceutical firms, including Merck, Eli Lilly, and Bristol-Myers Squibb, among others, to enhance its research and development efforts. Founded in 2003, Zymeworks continues to focus on developing innovative solutions for cancer and other serious diseases.

Imagia Cybernetics Inc. is a Montreal-based company that specializes in medical image analysis solutions aimed at cancer detection and management. The company focuses on early detection and quantification of cancer changes, which is crucial for improving patient outcomes. Imagia's Artificial Clinical Intelligence Platform delivers timely insights into primary tumors and metastasis, thereby personalizing the cancer care continuum for patients. Utilizing a unique approach called Deep Radiomics, which combines radiomics and deep learning, the platform analyzes routine clinical imaging data to identify robust biomarkers that can predict patient outcomes. By leveraging advancements in artificial intelligence and federated learning, Imagia enhances the capabilities of clinicians, enabling them to conduct predictive, diagnostic, and prescriptive analytics while maintaining data privacy.

PHEMI Systems Corporation specializes in developing a privacy, security, governance, and data management system tailored for Microsoft Azure. Founded in 2013 and based in Vancouver, Canada, the company provides the PHEMI Data Privacy Manager, a cloud-based solution designed for the healthcare sector. This system addresses the critical need for organizations to secure and govern access to privacy-sensitive information while facilitating compliance with privacy regulations. Optimized for Microsoft Azure, the software connects to numerous data sources and integrates seamlessly with popular data science and business analysis tools. Built on a privacy-by-design architecture, PHEMI Data Privacy Manager supports data sharing and offers a flexible usage-based pricing model, making it scalable for organizations of varying sizes.